Sun Pharma Takeover
- All
- News
- Videos
-
Dilip Shanghvi, Man Behind India's Best Stock, Now Faces His Greatest Test
Both Shanghvi's eye for value and his tenaciousness were exemplified in the 2010 takeover of Israel-based Taro Pharmaceutical Industries Ltd.
-
Open to Acquisitions but Selective With Targets: Sun Pharma
Fresh from its $4-billion takeover of Ranbaxy, Sun Pharmaceutical Industries says it is open to further acquisitions but will consider only targets "which will not require significant amount of management involvement".
-
Benefit of Ranbaxy Deal to Accrue in Few Years: Sun Pharma
Drug maker Sun Pharma has said that it will take a "few years" for it to realise the benefits of its $4-billion takeover of Ranbaxy, terming the deal as a "complex and large acquisition".
-
CCI Says Sun's Takeover of Ranbaxy May Hurt Competition
The Competition Commission of India (CCI) is still investigating the deal, but has formed a "prima facie opinion that the combination is likely to have an appreciable adverse effect on competition", according to a government statement on Thursday and a document posted on the regulator's website.
-
Andhra Pradesh High Court Lifts Stay on Sun Pharma's $3.2 Billion Ranbaxy Takeover
The Andhra Pradesh High Court on Saturday lifted a temporary stay it imposed on generic drugmaker Sun Pharmaceutical Industries Ltd's $3.2 billion takeover of Ranbaxy Laboratories Ltd, a lawyer involved in the case said, paving the way for both companies to complete the deal.
-
High Court Lifts Stay on Sun Pharma's $3.2 Billion Ranbaxy Takeover
The court last month ordered an "interim status quo" on the deal, pending a decision on a petition for a probe into alleged insider trading.
-
Nomura raises Ranbaxy to 'buy' on Sun Pharma takeover
Although Nomura says Ranbaxy shares look expensive on valuation, it notes the stock should now move in tandem with Sun Pharma, hence the steep increase in its target price.
-
Dilip Shanghvi, Man Behind India's Best Stock, Now Faces His Greatest Test
Both Shanghvi's eye for value and his tenaciousness were exemplified in the 2010 takeover of Israel-based Taro Pharmaceutical Industries Ltd.
-
Open to Acquisitions but Selective With Targets: Sun Pharma
Fresh from its $4-billion takeover of Ranbaxy, Sun Pharmaceutical Industries says it is open to further acquisitions but will consider only targets "which will not require significant amount of management involvement".
-
Benefit of Ranbaxy Deal to Accrue in Few Years: Sun Pharma
Drug maker Sun Pharma has said that it will take a "few years" for it to realise the benefits of its $4-billion takeover of Ranbaxy, terming the deal as a "complex and large acquisition".
-
CCI Says Sun's Takeover of Ranbaxy May Hurt Competition
The Competition Commission of India (CCI) is still investigating the deal, but has formed a "prima facie opinion that the combination is likely to have an appreciable adverse effect on competition", according to a government statement on Thursday and a document posted on the regulator's website.
-
Andhra Pradesh High Court Lifts Stay on Sun Pharma's $3.2 Billion Ranbaxy Takeover
The Andhra Pradesh High Court on Saturday lifted a temporary stay it imposed on generic drugmaker Sun Pharmaceutical Industries Ltd's $3.2 billion takeover of Ranbaxy Laboratories Ltd, a lawyer involved in the case said, paving the way for both companies to complete the deal.
-
High Court Lifts Stay on Sun Pharma's $3.2 Billion Ranbaxy Takeover
The court last month ordered an "interim status quo" on the deal, pending a decision on a petition for a probe into alleged insider trading.
-
Nomura raises Ranbaxy to 'buy' on Sun Pharma takeover
Although Nomura says Ranbaxy shares look expensive on valuation, it notes the stock should now move in tandem with Sun Pharma, hence the steep increase in its target price.
